It was a routine check-up by an internist that provided John Thompson his first indication of prostate cancer, an abnormal PSA. His PSA registered 19.4 ng/ml.
A urologist confirmed prostate cancer with a biopsy. John, who remembered seeing a brochure on ProstRcision, asked about the procedure as a treatment option, but was encouraged to take a surgical approach. “My wife and I have a lot of medical friends who, along with the urologist, recommended I have the prostate taken out,” he explains. “I followed what was then considered conventional wisdom.” In June 1993, John had a radical prostatectomy. Although surgical margins were negative, his PSA fell to a nadir of only 0.24 ng/ml.
By the fall of 1993, John’s PSA had increased, indicating the cancer was still in his system and gaining strength. According to his doctors, if he did nothing, he could live another two years; with hormone treatment, he’d have five to six years or possibly longer. However, John remembered ProstRcision and the benefits it had provided a radical prostatectomy patient. He scheduled an appointment with Dr. Critz right away.
Dr. Critz determined that the cancer appeared to be confined to the prostate bed. By now John’s PSA had risen to 2.6 ng/ml. In October 1995, John received a seed implant where the prostate used to be, followed by accelerator radiation.
“With radical prostatectomy, I was out of work for six weeks,” says John. “I never missed a day of work with ProstRcision.” Today, John is living without cancer. His PSA is undetectable, less than 0.1 ng/ml.
Note: The key to Mr. John’s case was his PSA nadir of 0.24 ng/ml, not 0.2 ng/ml or less, after radical prostatectomy. This PSA nadir showed that microscopic penetration cancer cells were left behind even though surgical margins were negative. The PSA nadir of 0.1 ng/ml after ProstRcision shows that the microscopic penetration cancer cells, left after surgery, were destroyed.